Replies to post #606968 on NorthWest Biotherapeutics Inc (NWBO)

[Dr Bala]

Totally nonsensical statements. Lack of understanding of the trial data.

[biosectinvestor]

You have no basis to say the 99 lived longer. Prove it.

There is no 99. The placebo arm was not fit for purpose because of the crossover. You can make up facts all you’d like but you can’t prove it because it is false.

If it were true, further, you could allege academic fraud by 70 researchers at top academic and research institutions. It’s a bogus argument.

But if you go too far, I bet it results in a serious lawsuit, maybe even in the UK. Good luck.

[dstock07734]

EX,

DCVax-L's approval is imminent no matter what the shorts are desperately doing.

Keep in mind at least 600 GBM patients receiving DCVax-L. There will be huge amount of real world data illustrating the enormous efficacy of DCVax-L. Recall what Professor Ashkan was confident that three shots was enough to prime the immune system. Most patients would have more than three shots. Just cannot imagine how good the results would be. It is no brainer that any RA on this planet would grant the approval.

[meirluc]

The 99 were randomized to receive injections of placebo prior to progression while the 233 received injections of DCVax-L prior to progression. The 99 lived longer.

Wrong. All the 331 DCVax-L trial patients received placebo prior to progression as did their matched ECAs but in addition to that, 232 trial patients (the treatment group) also received DCVax-L prior to progression, 64 trial patients received DCVax-L after progression and 29 trial patients failed to received DCVax-L before or after progression, most likely because most of them were rapid progressors and would have not have benefited from the vaccine.

The mOS of the 232 trial patients receiving the vaccine before progression was significantly longer than the mOS of the matched ECAs and the mOS of the 64 crossovers was even longer than the mOS of the 232 treatment patients. The longer mOS of those 232+64 patients can only be attributed to the administration of DCVax-L. The 29 trial patients whose mOS was likely much shorter than the mOS of the placebos, were most likely at a disadvantage because they were fast progressors who would no longer have been able to benefit from DCVax-L.

[biosectinvestor]

I will come back to you later, but there are very obvious and easy rebuttals to your very crude attempt at a statistical analysis. It’s wrong and presumes a whole set of false assumptions that are well proven false. And it’s mathematically false.